08.01.25 -- CDMOs Should Stop Stringing Biotechs Along

Novel technologies and therapies are helping drug developers to overcome challenges associated with the development of injectable and oral peptide formulations.

Emerging biotechs are behind many of the pharma industry’s latest therapeutic innovations. And while CDMOs are eager to work with them, they must learn to accommodate their unique needs.

Explore advanced approaches to designing robust amorphous formulations and optimizing spray drying processes tailored specifically to difficult-to-formulate compounds.

Recent shifts within the U.S. FDA reflect an increasingly complex tension between scientific rigor and accelerating political and economic pressures. See the newest developments and emerging focal points.

Discover how digital transformation is revolutionizing production processes to enable personalized medicine and improve patient outcomes across the healthcare industry.

To reduce CO₂ emissions and recycle higher volumes of solvent, drug manufacturers must engineer specialized approaches with flexible technologies that can accommodate different products.

In critical environments where mistakes have serious consequences, a disciplined, methodical approach isn't just a preference—it's the only path to success and long-term operational excellence.

We offer comprehensive solutions for Dry Powder Inhalers (DPIs), encompassing all stages from initial formulation screening to clinical-scale manufacturing.

The 362M two-sided labeling machine brings precision and versatility to your production line. This high-speed workhorse labels up to 200 products per minute, even those with challenging shapes.

We provide cGMP manufacturing services that scale with your development and approval milestones, ensuring a seamless transition from clinical to commercial supply.